论文部分内容阅读
目的观察阿德福韦酯联合拉米夫定治疗阿德福韦酯治疗48周后应答不佳,HBeAg阳性慢性乙型肝炎的疗效和安全性。方法选择2006年1月-2010年12月间阿德福韦酯治疗48周后乙型肝炎病毒DNA>104copies/mL的26例慢性乙型肝炎患者,给与拉米夫定(100 mg,1次/d)联合治疗。观察治疗12周,24周时的应答情况。结果所有纳入26例患者在联合拉米夫定优化治疗24周后,无论是病毒学应答还是血清学应答都获得显著的改善,无一例患者观察到有耐药以及药物不良反应发生。结论联合拉米夫定是对阿德福韦酯应答不佳慢性乙型肝炎患者安全有效的干预策略之一。
Objective To observe the efficacy and safety of adefovir dipivoxil combined with lamivudine in the treatment of adefovir dipivoxil after 48 weeks of poor response and HBeAg-positive chronic hepatitis B. Methods Twenty-six patients with chronic hepatitis B who had hepatitis B virus DNA> 104 copies / mL after 48 weeks of adefovir dipivoxil treatment between January 2006 and December 2010 were randomized to receive lamivudine (100 mg once / d) Combination therapy. Observed the treatment of 12 weeks, 24 weeks of response. Results All 26 patients enrolled in this study had a significant improvement in both virological and serological response to combined treatment with lamivudine for 24 weeks. None of the patients had any drug-resistant or adverse drug reactions observed. Conclusions Combined lamivudine is one of the safe and effective intervention strategies for adefovir dipivoxil patients with poor response to chronic hepatitis B.